Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Chen, Guohai ^a   Li, Wensheng ^b   Tzekov, Radouil ^c,d   Jiang, Fangzheng ^a   Mao, Sihong ^a   Tong, Yuhua ^a  

^a Quzhou People's Hospital   (China)

^b XIAMEN UNIVERSITY   (China)

^c ROSKAMP INSTITUTE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL MACULAR THICKNESS; DIABETIC MACULAR EDEMA; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; LOW LEVEL LASER THERAPY; META ANALYSIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; ADVERSE EFFECTS; DIABETIC RETINOPATHY; MACULAR EDEMA; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; HUMANS; LASER THERAPY; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANIBIZUMAB;

EID: 84919906858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115797     Document Type: Article

References (36)

1. Frank RN (2004). Diabetic retinopathy. N Engl J Med 350: 48-58.
2. Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, et al. (2010) Diabetic macular edema. Dev Ophthalmol 47: 73-110.
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91: 1464-1474.
4. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796-1806.
5. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
6. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, et al; Macugen Diabetic Retinopathy Study Group. (2005) A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747-1757.
7. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, et al. (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246: 483-489.
8. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, et al. (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399-2405.
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al; MARINA Study Group. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
10. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, et al; RIDE and RISE Research Group. (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120: 2013-2022.
11. Yanagida Y, Ueta T (2014) Systemic safety of ranibizumab for diabetic macular edema:meta-analysis of randomized trials. Retina 34: 629-635.
12. Abouammoh MA (2013) Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review. Can J Ophthalmol 48: 317-323.
13. Virgili G, Parravano M, Menchini F, Brunetti M (2012) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 12:CD007419.
14. Zechmeister-Koss I, Huic M (2012) Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br J Ophthalmol 96: 167-178.
15. Wang H, Sun X, Liu K, Xu X (2012) Intravitreal ranibizumab (Lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Cur Eye Res 37: 661-670.
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100.
17. Higgins JP, Green S (2008) Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. Hoboken, NJ: Wiley. 187-241p.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
19. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
20. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
21. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, et al; RESTORE study group. (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615-625.
22. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, et al. READ-2 Study Group. (2009) Primary end point (Six Months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 116: 2175-2181.
23. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, et al. READ-2 Study Group. (2010) Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 117: 2146-2151.
24. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, et al. READ-2 Study Group. (2013) Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 131: 139-145.
25. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al; Diabetic Retinopathy Clinical Research Network. (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064-1077.
26. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, et al; Diabetic Retinopathy Clinical Research Network. (2011) Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118: 609-614.
27. Berger A, Sheidow T, Li R, Rehel B, Takacsy FD, et al. (2013) A canadian 12-month, PhIIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: preliminary analysis ("RESPOND"). Can J Diabetes 37: S48.
28. Clinicaltrials.gov. Novartis. Efficacy and safety of ranibizumab (intravitreal injections) in patients with visual impairment due to diabetic macular edema (REVEAL). NCT00989989. Study results are available at ClinicalTrials.gov. Accessed 7 June 2014.
29. Clinicaltrials.gov. Novartis. Safety and efficacy of ranibizumab in diabetic macular edema (RELATION). NCT01131585. Study results are available at ClinicalTrials.gov. Accessed 7 June 2014.
30. Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, et al. (2014) A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol 157: 960-970.
31. Lang GE, Berta A, Eldem BM, Simader C, Sharp D, et al; RESTORE Extension Study Group. (2013) Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 120: 2004-2012.
32. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, et al; RESTORE Extension Study Group. (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121: 1045-1053.
33. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, et al; Diabetic Retinopathy Clinical Research Network. (2012) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119: 2312-2318.
34. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, et al. (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7: e42701.
35. Enders P, Muether PS, Hermann M, Ristau T, Fauser S. (2014) Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration. Retina DOI: 10.1097/IAE.0000000000000320.
36. Chen G, Li W, Tzekov R, Jiang F, Mao S, et al. (2014) Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. Retina DOI: 10.1097/IAE.0000000000000301.